51³Ô¹Ïapp

This research aims to develop quorum-sensing inhibitors, antimicrobial peptides, mimics and nitric oxide-releasing polymers, incorporating them into polymers and biomaterials to reduce device-related infections.

Competitive advantage

• Portfolio of antimicrobial and antibiofilm agents and scaffolds with novel mechanisms of action.
• Antimicrobial coatings technologies with demonstrated in-vivo efficacy at preventing device-related infections.
• Recognised international experts in the field of antimicrobial discovery and biomaterials.
• Outstanding track record in novel surface strategies for antimicrobial control with multiple industry-supported and government funding.

Impact

Up to 65% of all hospital acquired infections are caused by microbial colonisation of surfaces. This is a major health problem that can be prevented by new technologies which will save billions of dollars in healthcare costs and provide substantial economic benefits for industries. 

Successful outcomes

• completed Phase III clinical trials for antimicrobial contact lenses
  
• antimicrobial prototype devices for major biomedical companies.

Capabilities and facilities

• World class synthetic chemistry facilities including NMR and mass spectrometry, supported by a diverse range of imaging and surface characterisation facilities from the Mark Wainwright Analytical Centre.
• Fully equipped microbiology, molecular biology and cell culture laboratories.
• Clinically relevant animal models for device-related infections.

Our partners

• Prof Annelise Barron, Stanford University
• Prof David MacKenzie, University of Sydney
• Prof Krasimir Vasilev, Flinders University